LBH589 is a novel pan-histone deacetylase (HDAC) inhibitor that has potent antitumor activity in multiple myeloma and other hematological malignancies. However, its impact on the immune system has ...

IDH’s operations network extends beyond Egypt to Jordan, Sudan, and Nigeria. As of December 2022, IDH had 552 lab branches, up by 50 branches compared to 2021. It completed 32.7 million tests in 2022.